Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol versus trimetazidine as third-line antianginal therapy in symptomatic stable coronary artery disease
RBR-5kh98yPhase 4Recruiting
- Sponsor
- Faculdade de Medicina da Universidade Federal da Bahia
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in angina pectoris and coronary arteriosclerosis comparing Trimetazidine arm with Allopurinol arm (2 arms). Started Jul 2019; status: recruiting.
02
Drugs
allopurinoltrimetazidine
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on RBR-5kh98y.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5kh98y.